Bersanelli, Melissa
Cortellini, Alessio
Leonetti, Alessandro
Parisi, Alessandro
Tiseo, Marcello
Bordi, Paola
Michiara, Maria
Bui, Simona
Cosenza, Agnese
Ferri, Leonarda
Giudice, Giulia Claire
Testi, Irene
Rapacchi, Elena
Camisa, Roberta
Vincenzi, Bruno
Caruso, Giuseppe
Rauti, Antonio Natale
Arturi, Federica
Tucci, Marco
Santo, Valentina
Ricozzi, Valentina
Burtet, Vanessa
Sgargi, Paolo
Todeschini, Renata
Zustovich, Fable
Stucci, Luigia Stefania
Santini, Daniele
Buti, Sebastiano
Article History
Received: 13 June 2023
Accepted: 10 August 2023
First Online: 28 August 2023
Declarations
:
: Melissa Bersanelli received funding for the present study from Roche S.p.A. and Seqirus (through FICOG as Institution, no personal fees). She also received, outside the current work: research funding from Pfizer and Novartis (through Institutions); honoraria as a speaker at scientific events (personal fees) by BMS, MSD, IPSEN, Novartis, Astra Zeneca, Pierre Fabre, and Pfizer; as a consultant for advisory role (personal fees) by IPSEN, Novartis, Sanofi, Pierre-Fabre, and Merck; personal fees for copyright transfer by Sciclone Pharmaceuticals, Pierre-Fabre, MSD, IPSEN, Pfizer, and Sanofi. Alessandro Leonetti has received speakers’ fees for Astra-Zeneca and MSD, and has been on advisory boards for BeiGene, Sanofi and Novartis. Alessio Cortellini received grants for consultancies/advisory boards from BMS, MSD, OncoC4, IQVIA, Roche, GSK, AstraZeneca, Access Infinity, Ardelis Health and AlphaSight. He also received speaker fees from AstraZeneca, EISAI, Pierre-Fabre, MSD. Marcello Tiseo received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen, Merck, Sanofi. He also received institutional research grants from Astra-Zeneca, Boehringer Ingelheim. Sebastiano Buti received honoraria as a speaker at scientific events and in advisory role by BMS, Pfizer; MSD, Ipsen, Roche S.p.A., Eli-Lilly, AstraZeneca, and Novartis; he also received research funding from Novartis. All other authors declared no conflict of interest.
: The procedures followed were in accordance with the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the respective local ethical committees on human experimentation of each institution, after previous approval by the coordinating center (Servizio Sanitario Regionale Emilia-Romagna, Comitato Etico per Parma, protocol number 17259, approved on April 5th, 2017).
: Not applicable.